ADMET considerations for phosphodiesterase-5 inhibitors

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 10, 2012, Pages 1231-1245

  Rezvanfar, Mohammad Amin ^a   Rahimi, Hamid Reza ^a   Abdollahi, Mohammad ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Absorption; Distribution; Erectile dysfunction; Excretion; Metabolism; New drugs; NO cGMP pathway; Phosphodiesterase 5 inhibitors; Toxicity

Indexed keywords

AILDENAFIL; AVANAFIL; CYCLIC GMP; LODENAFIL; MIRODENAFIL; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; SK 3541; TADALAFIL; UDENAFIL; UK 103320; UNCLASSIFIED DRUG; VARDENAFIL;

AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; DEVELOPMENTAL DISORDER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HEARING LOSS; HEART DISEASE; HUMAN; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; NEUROLOGIC DISEASE; NONHUMAN; PRIAPISM; REPRODUCTIVE HEALTH; REVIEW; RISK ASSESSMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING; VISUAL DISORDER;

ADSORPTION; CYCLIC GMP; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HEARING; HEART; HEART DISEASES; HUMANS; NERVOUS SYSTEM DISEASES; NITRIC OXIDE; PHARMACEUTICAL PREPARATIONS; PHOSPHODIESTERASE 5 INHIBITORS; REPRODUCTION; TISSUE DISTRIBUTION;

EID: 84866515177     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.698610     Document Type: Review

References (128)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev 2004;3:711-15 (Pubitemid 39173511)
2. Penzotti JE, Landrum GA, Putta S. Building predictive ADMET models for early decisions in drug discovery. Curr Opin Drug Discov Devel 2004;7:49-60
3. Leonardi R, Alemanni M. The management of erectile dysfunction: Innovations and future perspectives. Arch Ital Urol Androl 2011;83(1):60-2
4. Salari P, Abdollahi M. Phosphodiesterase inhibitors in inflammatory bowel disease. Expert Opin Investig Drugs 2012;21(3):261-4
5. Khoshakhlagh P, Bahrololoumi-Shapourabadi M, Mohammadirad A, et al. Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress. Toxicol Mech Methods 2007;17(5):281-8 (Pubitemid 46956946)
6. Sung BJ, Hwang KY, Jeon YH, et al. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 2003;425(6953):98- 102 (Pubitemid 37101725)
7. Lin CS. Tissue expression, distribution, and regulation of PDE5. Int J Impot Res 2004;1:8-10
8. Jackson G, Gillies H, Osterloh I. Past, present, and future: A 7-year update of Viagra (sildenafil citrate). Int J Clin Pract 2005;59(6):680-91
9. Fekete A, Sasser JM, Baylis C. Chronic vasodilation produces plasma volume expansion and hemodilution in rats: Consequences of decreased effective arterial blood volume. Am J Physiol Renal Physiol 2011;300(1):F113-18
10. Bell AS, Palmer MJ. Novel Phosphodiesterase type 5 modulators: A patent survey (2008 - 2010). Expert Opin Ther Patents 2011;21(10):1631-41
11. Limin M, Johnsen N, Hellstrom WJ. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction. Expert Opin Investig Drugs 2010;19(11):1427-37
12. Rahimi R, Ghiasi S, Azimi H, et al. A review of the herbal phosphodiesterase inhibitors; future perspective of new drugs. Cytokine 2010;49(2):123-9
13. Arif SA, Poon H. Tadalafil: A long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension. Clin Ther 2011;33(8):993-1004
14. Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. N Engl J Med 2009;361:1864-71
15. Domek-Lopacinska K, Strosznajder JB. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res 2008;1216:68-77
16. Reneerkens OA, Rutten K, Steinbusch HW, et al. Selective phosphodiesterase inhibitors: A promising target for cognition enhancement. Psychopharmacology (Berl) 2009;202:419-43
17. Momtaz S, Abdollahi M. A comprehensive review of biochemical and molecular evidences from animal and human studies on the role of oxidative stress in aging: An epiphenomenon or the cause. Asian J Anim Vet Adv 2012;7(1):1-19
18. Khanavi M, Azimi H, Ghiasi S, et al. Specifying human platelet cAMP and cGMP phosphodiesterase inhibitory activity of the plants used in traditional Iranian medicine for the purpose of erectile dysfunction. Int J Pharmacol 2012;8(3):161-8
19. Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 2004;16(1):11-14
20. Rosen RC, Kostis JB. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003;92:9-18
21. Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol 2002;53(Suppl 1):61S-5S.
22. Kim TE, Kim BH, Kim JR, et al. Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. Br J Clin Pharmacol 2009;68(1):43-6
23. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: Absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002;53(1):5-12
24. Sussman DO. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. J Am Osteopath Assoc 2004;104:11-15
25. Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 2005;45:987-1003 (Pubitemid 41192358)
26. Walker DK, Ackland MJ, James GC, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999;29(3):297-310 (Pubitemid 29140098)
27. Ku WS, Cho HJ, Yoon IS, et al. Rapid and sensitive determination of udenafil in plasma by LC-MS/MS for intranasal pharmacokinetic study in rats. Chem Pharm Bull (Tokyo) 2011;59(9):1083-8
28. Steinhorn RH, Kinsella JP, Pierce C, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 2009;155(6):841-7
29. Jung SY, Seo YG, Kim GK, et al. Comparison of the solubility and pharmacokinetics of sildenafil salts. Arch Pharm Res 2011;34(3):451-4
30. Toque HA, Teixeira CE, Lorenzetti R, et al. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol 2008;591(1-3):189-95
31. Choi YH, Lee YS, Bae SH, et al. Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats. Biopharm Drug Dispos 2009;30(6):305-17
32. Shin KH, Kim BH, Kim TE, et al. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: An open-label, one-sequence, three-period, three-treatment crossover study. Clin Ther 2009;31(12):3009-20
33. Cho SH, Park H, Kim JH, et al. Effect of sildenafil on gastric emptying in healthy adults. J Gastroenterol Hepatol 2006;21(1 Pt 2):222-6
34. Alwaal A, Al-Mannie R, Carrier S. Future prospects in the treatment of erectile dysfunction: Focus on avanafil. Drug Des Devel Ther 2011;5:435-43
35. Jung J, Choi S, Cho SH, et al. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: A single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers. Clin Ther 2010;32(6):1178-87
36. Silva AC, Toffoletto O, Lucio LA, et al. Cardiovascular repercussion of lodenafil carbonate, a new PDE5 inhibitor, with and without alcohol consumption. Arq Bras Cardiol 2010;94(2):150-6; 160-7, 152-8
37. Jung JY, Kim SK, Kim BS, et al. The penile erection efficacy of a new phosphodiesterase type 5 inhibitor, mirodenafil (SK3530), in rabbits with acute spinal cord injury. J Vet Med Sci 2008;70(11):1199-204
38. Kelly RJ, Robey RW, Chen CC, et al. A pharmacodynamic study of the p-glycoprotein antagonist CBT-1(R) in combination with paclitaxel in solid tumors. Oncologist 2012;17(4):512
39. Di X, Gennings C, Bear HD, et al. Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells. Breast Cancer Res Treat 2010;124(2):349-60
40. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999;33(1):273-82
41. CDER/FDA. NDA 021400 levitra (Vardenafil Hydrochloride) tablets -clinical pharmacology/biopharmaceutics review. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; Silver Spring, MD: 2003
42. CDER/FDA. NDA 021368 cialis (Tadalafil) tablets-clinical pharmacology/biopharmaceutics review. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; Silver Spring, MD: 2003
43. Mehrotra N, Gupta M, Kovar A, et al. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 2007;19(3):253-64 (Pubitemid 46701452)
44. Milligan PA, Marshall SF, Karlsson MO. A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol 2002;53(Suppl 1):45S-52S
45. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270(1):414-23 (Pubitemid 24229655)
46. Hyland R, Roe EG, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. Br J Clin Pharmacol 2001;51(3):239-48 (Pubitemid 32391501)
47. Warrington JS, Shader RI, von Moltke LL, Greenblatt DJ. In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions. Drug Metab Dispos 2000;28(4):392-7 (Pubitemid 30185676)
48. Wrishko RE, Dingemanse J, Yu A, et al. Pharmacokinetic interaction between tadalafiland bosentan in healthy male subjects. J Clin Pharmacol 2008;48(5):610-18 (Pubitemid 351503516)
49. Shon JH, Ku HY, Bae SY, et al. The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. Pharmacogenet Genomics 2011;21(12):820-8
50. Lee YS, Choi YH, Kim TK, et al. Pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous and oral administration of mirodenafil to streptozotocin-induced diabetes mellitus rats. Xenobiotica 2010;40(2):129-37
51. Lee HS, Park EJ, Ji HY, et al. Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil. Xenobiotica 2008;38(1):21-33
52. Homolya L, Varadi A, Sarkadi B. Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors 2003;17(1-4):103-14 (Pubitemid 37267146)
53. Ding PR, Tiwari AK, Ohnuma S, et al. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One 2011;6(4):e19329
54. Medana C, Calza P, Giancotti V, et al. Horse metabolism and the photocatalytic process as a tool to identify metabolic products formed from dopant substances: The case of sildenafil. Drug Test Anal 2011;3(10):724-34
55. Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 2004;4(5):281-97 (Pubitemid 39429835)
56. Al-Ghazawi MA, Tutunji MS, AbuRuz SM. The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers. Eur J Clin Pharmacol 2010;66(2):159-63
57. Reffelmann T, Kloner RA. Vardenafil: A selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction. Expert Opin Pharmacother 2007;8(7):965-74 (Pubitemid 351227484)
58. Corona G, Razzoli E, Forti G, et al. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 2008;31(9):799-808
59. Wilner K, Laboy L, LeBel M. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. Br J Clin Pharmacol 2002;53(Suppl 1):31S-6S
60. Muirhead GJ, Faulkner S, Harness JA, Taubel J. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br J Clin Pharmacol 2002;53(Suppl 1):37S-43S
61. Available from: Http://www.fda.gov/medwatch/safety/2007/Jul-PI/Viracept- PI.pdf
62. Sekar V, Lefebvre E, De Marez T, et al. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: Phase I randomized, open-label, two-way crossover study. Clin Drug Investig 2008;28(8):479-85 (Pubitemid 351948050)
63. Burgess G, Hoogkamer H, Collings L, Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008;64(1):43-50
64. Stavros F, Kramer WG, Wilkins MR. The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol 2010;69(1):23-6
65. Hesse C, Siedler H, Burhenne J, et al. Fluvoxamine affects sildenafil kinetics and dynamics. J Clin Psychopharmacol 2005;25(6):589-92 (Pubitemid 41669056)
66. Giuliano F, Jackson G, Montorsi F, et al. Safety of sildenafil citrate: Review of 67 double-blind placebocontrolled trials and the postmarketing safety database. Int J Clin Pract 2010;64(2):240-55
67. Dworzanski W, Jaskolska A, Szumiło M, et al. Cardiovascular complications of phosphodiesterase-5 inhibitors. Pol Merkur Lekarski 2011;30(176):139-42
68. Toshiyasu A, Tetsuya I, Katsurou T, et al. Comparative study for the treatment of erectile dysfunction with sildenafil and vardenafil--multi-centric research in Nagano City. Nihon Hinyokika Gakkai Zasshi 2009;100(1):1-6
69. Taylor J, Baldo OB, Storey A, et al. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int 2009;103(10):1392-5
70. Cote RH. Characteristics of photoreceptor PDE (PDE6): Similarities and differences to PDE5. Int J Impot Res 2004;16(1):S28-33
71. Fraunfelder FT, Fraunfelder FW. Erectile dysfunction agents. In: Drug-induced ocular side effects. 5th edition. Butterworth-Heineman; Boston, MA, 2001. p. 367
72. Laties A, Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med 2006;3(1):12-27
73. Laties AM. Vision disorders and phosphodiesterase type 5 inhibitors: A review of the evidence to date. Drug Saf 2009;32(1):1-18
74. Azzouni F, Abu samra K. Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. J Sex Med 2011;8(10):2894-903
75. Aliferis K, Petropoulos IK, Farpour B, et al. Should central serous chorioretinopathy be added to the list of ocular side effects of phosphodiesterase 5 inhibitors? Ophthalmologica 2012;227(2):85-9
76. Michelakis E, Tymchak W, Archer S. Sildenafil: From the bench to the bedside. CMAJ 2000;163(9):1171-5
77. Eros D, Szantai C, Kiss R, et al. Structure-activity relationships of PDE-5 inhibitors. Curr Med Chem 2008;15:1570-85
78. Kontaras K, Varnavas V, Kyriakides ZS. Does sildenafil cause myocardial infarction or sudden cardiac death? Am J Cardiovasc Drugs 2008;8(1):1-7 (Pubitemid 351311514)
79. Maddox PT, Saunders J, Chandrasekhar SS. Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology. Laryngoscope 2009;119(8):1586-9
80. Khan AS, Sheikh Z, Khan S, et al. Viagra deafness--sensorineural hearing loss and phosphodiesterase-5 inhibitors. Laryngoscope 2011;121(5):1049-54
81. Abbott D, Comby P, Charnel C, et al. Preclinical safety profile of sildenafil. Int J Impot Res 2004;16(6):498-504 (Pubitemid 39664857)
82. Villanueva-Garcia D, Mota-Rojas D, Hernandez-Gonzalez R, et al. A systematic review of experimental and clinical studies of sildenafil citrate for intrauterine growth restriction and pre-term labour. J Obstet Gynaecol 2007;27(3):255-9 (Pubitemid 46676394)
83. Glenn DR, McClure N, Cosby SL, et al. Sildenafil citrate (Viagra) impairs fertilization and early embryo development in mice. Fertil Steril 2009;91(3):893-9
84. Refuerzo JS, Sokol RJ, Aranda JV, et al. Sildenafil citrate and fetal outcome in pregnant rats. Fetal Diagn Ther 2006;21(3):259-63
85. Abou-Tarboush FM, Abdel-Samad MF, Al-Meteri MH. Developmental toxicity of orally administered sildenafil citrate (Viagra) in SWR/J mice. Saudi J Biol Sci 2011;18:135-9
86. Bingham J, Sudarsanam S, Srinivasan S. Profiling human phosphodiesterase genes and splice isoforms. Biochem Biophys Res Commun 2006;350(1):25-32 (Pubitemid 44466570)
87. Hellstrom WJ, Overstreet JW, Yu A, et al. Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol 2003;170:887-91 (Pubitemid 36999583)
88. Pomara G, Morelli G, Canale D, et al. Alterations in sperm motility after acute oral administration of sildenafil or tadalafil in young, infertile men. Fertil Steril 2007;88:860-5 (Pubitemid 47498359)
89. Hellstrom WJ, Gittelman M, Jarow J, et al. An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20 mg: Results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. Eur Urol 2008;53(5):1058-65 (Pubitemid 351434491)
90. Dimitriadis F, Giannakis D, Pardalidis N, et al. Effects of phosphodiesterase-5 inhibitors on sperm parameters and fertilizing capacity. Asian J Androl 2008;10(1):115-33
91. Dimitriadis F, Tsambalas S, Tsounapi P, et al. Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: A randomized trial. BJU Int 2010;106(8):1181-5
92. Purvis K, Muirhead GJ, Harness JA. The effects of sildenafil on human sperm function in healthy volunteers. Br J Clin Pharmacol 2002;53(Suppl 1):53S-60S
93. Mostafa T. Oral phosphodiesterase-5 inhibitors and sperm functions. Int J Impot Res 2008;20(6):530-6
94. Khalaf MA, Abbas MF, El-Fakahany HM. Effects of chronic tadalafil use on the testes and sperm parameters of old albino rats. Andrologia 2012;44(1):370-5
95. Jarrar BM. Histological alterations in the testicular tissue induced by sildenafil overdoses. Drug Metab Lett 2011;5(2):99-103
96. Jannini EA, DeRogatis LR, Chung E, et al. How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors. J Sex Med 2012;9(1):26-33
97. Eardley I, Mirone V, Montorsi F, et al. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 2005;96:1323-32 (Pubitemid 41743933)
98. Eardley I, Montorsi F, Jackson G, et al. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy: Post hoc analysis of data from a multicentre, randomized, open-label, crossover study. BJU Int 2007;100:122-9 (Pubitemid 46878565)
99. Tolra JR, Campana JM, Ciutat LF, et al. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 2006;3:901-9 (Pubitemid 44269546)
100. Von Keitz A, Rajfer J, Segal S, et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004;45:499-507 (Pubitemid 38376216)
101. Govier F, Potempa AJ, Kaufman J, et al. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction. Clin Ther 2003;25:2709-23 (Pubitemid 37510585)
102. Dean J, Hackett GI, Gentile V, et al. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: Results of a multicenter, randomized, open-label, crossover study. J Sex Med 2006;3:650-61
103. Ozgur BC, Gonenc F, Yazicioglu AH. Sildenafil or vardenafil nonresponders' erectile response to tadalafil. Urol J 2009;6(4):267-71
104. Tsertsvadze A, Fink HA, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: A systematic review and meta-analysis. Ann Intern Med 2009;151:650-61
105. Kumar P, Francis GS, Tang WH. Phosphodiesterase 5 inhibition in heart failure: Mechanisms and clinical implications. Nat Rev Cardiol 2009;6:349-55
106. De LaVega AJ, Derk CT. Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: A novel indication. Expert Opin Investig Drugs 2009;18:23-9
107. Wang C. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol 2010;20(1):49-54; Review
108. Zhang X, Zang N, Wei Y, et al. Testosterone regulates smooth muscle contractile pathways in the rat prostate: Emphasis on PDE5 signaling. Am J Physiol Endocrinol Metab 2012;302(2):243-53
109. Tinsley HN, Gary BD, Keeton AB, et al. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther 2009;8(12):3331-40
110. Arozarena I, Sanchez-Laorden B, Packer L, et al. Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 2009;19:45-57
111. Houslay MD. Hard times for oncogenic BRAF-expressing melanoma cells. Cancer Cell 2011;19:3-4
112. Ghiasi S, Ghiasi S, Abdollahi M. A review on the potential benefits of phosphodiesterase inhibitors in various models of toxicities in animals. Asian J Anim Vet Adv 2012;7(3):210-24
113. Mohammadi M, Atashpour S, Pourkhalili N, et al. Comparative improvement in function of isolated rat Langerhans islets by various phosphodiesterase 3, 4 and 5 inhibitors. Asian J Anim Vet Adv 2011;6(12):1233-40
114. Azadbar M, Ranjbar A, Hosseini-Tabatabaei A, et al. Interaction of phosphodiesterase 5 inhibitor with malathion on rat brain mitochondrial-bound hexokinase activity. Pestic Biochem Physiol 2009;95:121-5
115. Ranjbar A, Ghahremani MH, Sharifzadeh M, et al. Protection by pentoxifylline of malathion-induced toxic stress and mitochondrial damage in rat brain. Hum Exp Toxicol 2010;29:851-64
116. Ghafour-Rashidi Z, Dermenaki-Farahani D, Aliahmadi A, et al. Protection by cAMP and cGMP phosphodiesterase inhibitors of diazinon-induced hyperglycemia and oxidative/nitrosative stress in rat Langerhans islets cells: Molecular evidence for involvement of non-cholinergic mechanisms. Pestic Biochem Physiol 2007;87:261-70 (Pubitemid 46188336)
117. Milani E, Nikfar S, Khorasani K, et al. Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp Biochem Physiol C Toxicol Pharmacol 2005;140(2):251-5 (Pubitemid 40720044)
118. Abdollahi M, Chan TS, Subrahmanyam V, et al. Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenolysis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol Cell Biochem 2003;252:205-11 (Pubitemid 37220750)
119. Hoseini S, Esmaily H, Mohammadirad A, et al. Effects of sildenafil a phosphodiesterase 5 inhibitor on rat liver cell key enzymes of gluconeogenesis and glycogenolysis. Int J Pharmacol 2006;2(3):280-5
120. Kotera J, Fujishige K, Omori K. Immunohistochemical localization of cGMP-binding cGMP-specific phosphodieterase (PDE 5) in rat tissues. J Histochem Cytochem 2000;48:685-93 (Pubitemid 30233192)
121. Ghosh R, Sawant O, Ganpathy P, et al. Phosphodiesterase inhibitors: Their role and implications. IJPTR 2009;1:1148-60
122. Schwartz BG, Levine LA, Comstock G, et al. Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol 2012;59(1):9-15; Review
123. Kloner RA, Comstock G, Levine LA, et al. Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors. Expert Opin Pharmacother 2011;12(15):2297-313; Review
124. Kukreja RC, Salloum FN, Das A, et al. Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases. Exp Clin Cardiol 2011;16(4):30-5
125. Badri S, Dashti-Khavidaki S, Lessan-Pezeshki M, et al. A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. J Pharm Pharm Sci 2011;14(1):128-37
126. Radfar M, Larijani B, Hadjibabaie M, et al. Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, double-blind placebocontrolled clinical trial. Biomed Pharmacother 2005;59:302-6 (Pubitemid 41058720)
127. Dorsey P, Keel C, Klavens M, Hellstrom WJ. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin Pharmacother 2010;11(7):1109-22; Review 128.
128. Yadav DK, Khan F, Negi AS. Pharmacophore modeling, molecular docking, QSAR, and in silico ADMET studies of gallic acid derivatives for immunomodulatory activity. J Mol Model 2012;18(6):2513-25